Medpace Holdings Stock News

Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q4 2021 Results - Earnings Call Transcript

Medpace Holdings Inc''s (NASDAQ: MEDP ) Q4 revenue increased 18.8% Y/Y to $308.6 million , missing the consensus of $309.04 million. On a constant currency organic basis, revenue increased 19.2%. As of December 31, 2021, Backlog grew 29.5% to $1.99 billion. Net new business awards were $458.7 million, representing a net … Full story available on Benzinga.com

Medpace press release (NASDAQ:MEDP): Q4 GAAP EPS of $1.32 beats by $0.07.Revenue of $308.55M (+18.8% Y/Y) misses by $0.48M.

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter and Full Year 2021 Financial Results Revenue for the three months ended December 31, 2021 increased 18.8% to $308.6 million, compared to $259.7 million for the comparable prior-year period. Revenue for the year ended December 31, 2021 increased 23.4% to $1,142.4 million, compared to $925.9 million for the ye

Medpace (MEDP) delivered earnings and revenue surprises of 5.60% and 0.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Medpace (NASDAQ:MEDP) is scheduled to announce Q4 earnings results on Monday, February 14th, after market close.The consensus EPS Estimate is $1.29 (-4.4% Y/Y) and the consensus

Related Stocks: CNXC , VRNT , CRUS , CAH , CGNT , MNDT , CALX , AIT , MEDP , NBIX , CSGS , CRNC , CTXS , AMBA , CRL , SEDG , PRFT , TCEHY , HOLI , WK , HLNE , KD ,

The "Physical, Engineering, And Life Sciences Global Market Report 2022" report has been added to ResearchAndMarkets.com''s offering. The global physical, engineering, and life sciences market is expected to grow from $391.44 billion in 2021 to $443.17 billion in 2022 at a compound annual growth rate (CAGR) of 13.2%. The market is expected to reach $687.28 billion in 2026 at a CAGR of 11.6%. Major players in the physical, engineering and life sciences market are IQVIA Holdings Inc, Battelle Memorial Institute, Syneos Health Inc, PRA Health Sciences Inc, Charles River Laboratories International Inc, PAREXEL International Corporation, Pharmaceutical Product Development LLC, Medpace Holdings Inc, Albany Molecular Research Inc and Hitachi High Technologies America Inc. Physical, Engineering, and Life Sciences establishments are engaged in conducting research and experimental development in physical, engineering, and life sciences such as agriculture, environmental, botany, electronics, chemistry, fisheries, forests, mathematics, veterinary and other allied subjects.

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DENVER , Feb. 7, 2022 /PRNewswire-PRWeb/ -- At the SCOPE Summit ( Feb 7-10, 2022 ), ClinOne will unveil its new brand, product marketecture, and messaging and showcase how its mission to connect, inform and empower clinical trials patients is making it one of the fastest growing companies to watch in clinical technology. "If anything is clear since the last SCOPE two years ago, it''s that ''good enough'' is no longer good enough," said Kristopher Sarajian ( LinkedIn ), VP of Marketing at ClinOne. "Remote solutions, technology standards, delivery timelines, flexible integrations, and UX have all taken massive steps forward. So, while it''s easy to dismiss a rebrand as a new logo, colors, and website and we''ll certainly have all that at this pivotal moment in the evolution of clinical trials it represents much more. That''s why I''m excited for you to meet the new ClinOne. Together, we will provide the results you need and the experience your patients deserve." ClinOne will have an active role at the SCOPE Summit.

Related Stocks: MEDP ,

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August J. Troendle sold 30,605 shares of the companys stock in a transaction that occurred on Friday, December 17th. The stock was sold at an average price of $213.59, for a total transaction of $6,536,921.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is [] The post Insider Selling: Medpace Holdings, Inc. (NASDAQ:MEDP) CEO Sells 30,605 Shares of Stock appeared first on ETF Daily News .